Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Who can apply?

Principle Investigators should apply for fellowship funding to support clinical (Grade E64) or basic research scientists (Grade 7/8) committed to translational science and interested in obtaining experience with drug development in an industrial setting. 

Fellowship applications may include a named fellow, but this is not mandatory. It is expected that a suitable fellowship candidate will be identified by the Principle Investigator within 6 months of notification of successful project selection.

Principle Investigators can have a maximum of 2 Oxford-BMS Fellowships running at any one time (though you can be a co-investigator on other fellowships if you are already lead investigator on 2 projects).


The proposed fellowship needs to align with BMS’s fields of interest as listed below:

1. Novel targets, biomarkers, cellular therapeutic approaches, or translational models in one of the following areas:

        • immuno-oncology;
        • solid tumour targets including drug resistance
        • neurodegenerative and neuroinflammatory diseases including Alzheimer’s, Parkinson’s, ALS, FTD and MS;
        • fibrosing disorders including IPF, scleroderma, and Renal Fibrosis;
        • rheumatic and dermatologic disorders including RA, SLE, spondyloarthropathies, psoriasis and atopic dermatitis; 
        • hematologic disorders including AML, Myeloma, DLBCL;
        • chronic heart failure (either with preserved or reduced ejection fraction).

2. Methods for evaluating biochemical, cellular, tissue and phenotypic consequences of modulating epigenetic targets.

3. Methods for immuno-phenotyping of human subjects in oncology and autoimmunity

4. Novel imaging approaches to measuring disease activity in the above areas.